Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family, "RS7 antibodies," were issued as Patent No. 1,002,443 in Korea.

23 Dec 2010

Arena, Eisai complete lorcaserin NDA end-of-review meeting with FDA

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application (NDA).

22 Dec 2010

USPTO terminates interference proceeding in favor of PDL's '089 Patent

PDL BioPharma, Inc. today announced that on December 15, 2010, the U.S. Patent and Trademark Office (the PTO) terminated its interference proceeding between certain claims of the Company's Queen et al., U.S. Patent No. 5,585,089, (the '089 Patent) and certain pending claims of Adair et al., U.S. Application No. 08/846,658, (the '658 Application) in favor of the Company's '089 Patent.

22 Dec 2010

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

22 Dec 2010

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Biogen Idec and Elan Corporation, plc announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective TYSABRI Prescribing Information and Summary of Product Characteristics.

22 Dec 2010

Biovest issues FAQ update on BiovaxID personalized cancer vaccine

Biovest International, Inc. today issued the following update in the form of a "Frequently Asked Questions" report in response to the high volume of inquiries received following the Company's recent presentation at the 2010 American Society of Hematology Annual Meeting (ASH 2010) in Orlando, Florida.

21 Dec 2010

BioInvent, Japanese pharmaceutical extends partnership for therapeutic candidate development

BioInvent International AB today announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group.

21 Dec 2010

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

20 Dec 2010

Gilead to acquire Arresto

Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.

20 Dec 2010

'Histone code' needs to be used with caution

The function of histones -- the proteins that enable yards of DNA to be crammed into a single cell -- depends on a number of chemical tags adorning their exterior. This sophisticated chemical syntax for packaging DNA into tight little coils or unraveling it again -- called the "histone code" -- is the latest frontier for researchers bent on understanding how genetics encodes life.

17 Dec 2010

Genentech confirms EMA, FDA updates on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, confirmed that following the reviews of Avastin® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:

17 Dec 2010

NovImmune obtains additional financing of CHF 20 million

NovImmune announced today, following its July 2010 deal with Genentech/Roche, that it obtained further financing of CHF 20 million. The series B financing round of CHF 20M was led by BZ Bank Aktiengesellschaft.

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

Study: Biomarkers may aid in early diagnosis of breast cancer

Using a new, powerful method for rapidly screening molecules associated with disease, proteomics expert Joshua LaBaer and colleagues from the Biodesign Institute at Arizona State University have identified a broad panel of 28 early predictors, or biomarkers, that may one day aid in the early diagnosis of breast cancer.

17 Dec 2010

Gen-Probe announces GTI Diagnostics acquisition from Riverside Company

Gen-Probe Incorporated announced today that the Company has acquired GTI Diagnostics, a privately held specialty diagnostics company focused on the transplantation, blood bank and specialty coagulation markets, for $53 million in cash.

17 Dec 2010

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Novavax, Inc. announced today that the company's Phase I clinical trial to evaluate a new vaccine candidate to prevent respiratory syncytial virus (RSV) infection has been cleared by the U.S. Food and Drug Administration (FDA) and is no longer on clinical hold. In November, the company reported that it had received a question from the FDA regarding chemistry, manufacturing and controls (CMC) that has now been resolved.

16 Dec 2010

Adimab initiates new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences

Adimab, Inc., a technology leader in the discovery of fully human antibodies, today announced the initiation of three new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences. Over the past 18 months Adimab has established collaborations with several leading Pharmaceutical companies including: Merck, Roche, Novartis, Pfizer, and now Eli Lilly, Genentech, and Human Genome Sciences.

16 Dec 2010

Epitomics enters contract with SAIC Frederick to develop rabbit monoclonal antibodies for CPTC program

Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).

16 Dec 2010

New finding sheds light on how HIV eludes treatment by mutating

The virus that causes AIDS is chameleon-like in its replication. As HIV copies itself in humans, it constantly mutates into forms that can evade even the best cocktail of current therapies. Understanding exactly how HIV cells change as they reproduce is key to developing better tests and treatments for patients.

16 Dec 2010